Gambaran Umum
Adverum Biotechnologies, Inc., based in the United States, operates within the biotechnology industry, focusing on the development of gene therapy products. The company's primary project revolves around innovative therapies for ocular and rare diseases, using its proprietary vector platforms to address conditions like age-related macular degeneration. Adverum is pioneering in the area of adeno-associated virus (AAV) vectors, a technology that facilitates the delivery of genetic material into cells. Their lead product candidate, ADVM-022, is an investigational gene therapy designed for the treatment of wet age-related macular degeneration, representing a significant advancement in the field and demonstrating their commitment to addressing unmet medical needs through gene therapy solutions.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Adverum Biotechnologies, Inc. per 2025 Jun 30 adalah 1.00 MM.
- Nilai operating income untuk Adverum Biotechnologies, Inc. per 2025 Jun 30 adalah -175.13 MM.
- Nilai net income untuk Adverum Biotechnologies, Inc. per 2025 Jun 30 adalah -169.49 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 1.00 | -175.13 | -169.49 |
2025-03-31 | 1.00 | -158.18 | -150.80 |
2024-12-31 | 1.00 | -139.16 | -130.93 |
2024-09-30 | 1.00 | -122.43 | -113.44 |
2024-06-30 | 0.00 | -127.74 | -119.19 |
2024-03-31 | 0.00 | -127.90 | -120.21 |
2023-12-31 | 3.60 | -128.94 | -122.12 |
2023-09-30 | 3.60 | -126.96 | -126.19 |
2023-06-30 | 3.60 | -133.47 | -133.43 |
2023-03-31 | 3.60 | -142.42 | -145.68 |
2022-12-31 | -150.31 | -154.54 | |
2022-09-30 | 0.00 | -155.61 | -156.21 |
2022-06-30 | 0.00 | -152.03 | -154.44 |
2022-03-31 | 0.00 | -154.55 | -155.01 |
2021-12-31 | 7.50 | -145.06 | -145.54 |
2021-09-30 | 7.50 | -147.01 | -148.76 |
2021-06-30 | 7.50 | -137.56 | -138.17 |
2021-03-31 | 7.50 | -122.80 | -123.04 |
2020-12-31 | -117.95 | -117.51 | |
2020-09-30 | 0.00 | -101.22 | -98.80 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -8.10.
- laba per saham yang terdilusi untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -8.10.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -8.10 | -8.10 |
2025-03-31 | -7.22 | -7.22 |
2024-12-31 | -6.62 | |
2024-09-30 | -6.63 | -6.63 |
2024-06-30 | -8.27 | -8.27 |
2024-03-31 | -10.28 | -10.28 |
2023-12-31 | -12.11 | |
2023-09-30 | -12.56 | -12.56 |
2023-06-30 | -13.33 | -13.33 |
2023-03-31 | -14.62 | -14.62 |
2022-12-31 | -15.57 | |
2022-09-30 | -15.81 | -15.81 |
2022-06-30 | -15.68 | -15.71 |
2022-03-31 | -15.78 | -15.78 |
2021-12-31 | -14.85 | |
2021-09-30 | -15.20 | -15.20 |
2021-06-30 | -14.46 | -14.42 |
2021-03-31 | -13.50 | -13.50 |
2020-12-31 | -13.80 | |
2020-09-30 | -12.83 | -12.83 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Adverum Biotechnologies, Inc. per 2025 Jun 30 adalah -130.91 MM.
- Nilai cash from investing activities untuk Adverum Biotechnologies, Inc. per 2025 Jun 30 adalah 45.65 MM.
- Nilai kas dari aktivitas pendanaan untuk Adverum Biotechnologies, Inc. per 2025 Jun 30 adalah 0.36 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -130.91 | 45.65 | 0.36 |
2025-03-31 | -111.99 | 11.42 | 0.12 |
2024-12-31 | -92.46 | -41.89 | 120.00 |
2024-09-30 | -85.54 | -47.58 | 119.93 |
2024-06-30 | -88.33 | -16.04 | 119.83 |
2024-03-31 | -91.73 | 53.31 | 119.95 |
2023-12-31 | -90.90 | 96.88 | 0.07 |
2023-09-30 | -88.05 | 108.99 | 0.14 |
2023-06-30 | -95.94 | 115.16 | 0.25 |
2023-03-31 | -101.57 | 78.87 | 0.60 |
2022-12-31 | -108.09 | 141.72 | 0.61 |
2022-09-30 | -115.43 | 163.37 | 0.74 |
2022-06-30 | -109.42 | 149.47 | 0.74 |
2022-03-31 | -114.45 | 156.51 | 0.90 |
2021-12-31 | -107.83 | 78.71 | 2.40 |
2021-09-30 | -104.24 | 66.40 | 2.40 |
2021-06-30 | -104.99 | -76.44 | 206.65 |
2021-03-31 | -87.98 | -202.84 | 208.87 |
2020-12-31 | -79.29 | -280.17 | 355.99 |
2020-09-30 | -71.90 | -310.95 | 382.38 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/libro untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah 1.70.
- p/tbv untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah 1.70.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | 1.70 | 1.70 | |
2025-03-31 | -1.02 | 0.67 | 0.67 |
2024-12-31 | 0.68 | 0.68 | |
2024-09-30 | -1.45 | 0.86 | 0.86 |
2024-06-30 | -1.28 | 0.79 | 0.79 |
2024-03-31 | -2.60 | 3.65 | 3.65 |
2023-12-31 | -0.60 | 0.74 | 0.74 |
2023-09-30 | -1.12 | 1.14 | 1.14 |
2023-06-30 | -1.10 | 1.01 | 1.01 |
2023-03-31 | -0.46 | 0.39 | |
2022-12-31 | 0.28 | 0.28 | |
2022-09-30 | 0.39 | 0.39 | |
2022-06-30 | -0.76 | 0.42 | 0.42 |
2022-03-31 | -0.88 | 0.41 | 0.41 |
2021-12-31 | -1.16 | 0.50 | 0.50 |
2021-09-30 | -1.54 | 0.56 | 0.56 |
2021-06-30 | |||
2021-03-31 | -0.91 | 0.27 | 0.27 |
2020-12-31 | -0.95 | 0.26 | 0.26 |
2020-09-30 | -1.12 | 0.24 | 0.24 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah 35.52.
- EBIT (3 tahun) / EV untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah 30.24.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | 35.52 | 30.24 |
2025-03-31 | -31.24 | -38.80 |
2024-12-31 | -20.21 | -26.03 |
2024-09-30 | -5.93 | -7.50 |
2024-06-30 | 24.12 | 29.25 |
2024-03-31 | -0.52 | -0.61 |
2023-12-31 | 4.30 | 4.89 |
2023-09-30 | -3.47 | -3.69 |
2023-06-30 | -1.58 | -1.58 |
2023-03-31 | -53.72 | -50.01 |
2022-12-31 | 6.10 | 5.24 |
2022-09-30 | -61.59 | -53.30 |
2022-06-30 | -5.46 | -4.45 |
2022-03-31 | -1.54 | -1.20 |
2021-12-31 | -1.06 | -0.79 |
2021-09-30 | -0.83 | -0.60 |
2021-06-30 | ||
2021-03-31 | -1.84 | -1.34 |
2020-12-31 | -2.38 | -1.74 |
2020-09-30 | -2.57 | -2.02 |
Efektivitas Manajemen
- roa untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -0.59.
- roe untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -0.90.
- roic untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -1.26.
- croic untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -0.84.
- ocroic untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -0.94.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.59 | -0.90 | -1.26 | -0.84 | -0.94 |
2025-03-31 | -0.35 | -0.52 | -0.43 | -0.06 | -0.39 |
2024-12-31 | -0.54 | -1.13 | -0.43 | -0.06 | -0.39 |
2024-09-30 | -0.51 | -0.97 | -0.41 | 0.06 | -0.37 |
2024-06-30 | -0.41 | -0.72 | -0.44 | 0.32 | -0.36 |
2024-03-31 | -0.38 | -0.65 | -0.74 | 0.04 | -0.57 |
2023-12-31 | -0.38 | -0.61 | -0.71 | 0.12 | -0.49 |
2023-09-30 | -0.36 | -0.55 | -0.60 | 0.09 | -0.43 |
2023-06-30 | -0.39 | -0.60 | -0.60 | 0.09 | -0.43 |
2023-03-31 | -0.38 | -0.55 | -0.57 | -0.09 | -0.40 |
2022-12-31 | -0.32 | -0.45 | -0.50 | 0.16 | -0.37 |
2022-09-30 | -0.31 | -0.45 | -0.50 | 0.16 | -0.37 |
2022-06-30 | -0.29 | -0.41 | -0.44 | 0.12 | -0.31 |
2022-03-31 | -0.32 | -0.35 | -0.40 | 0.11 | -0.30 |
2021-12-31 | -0.31 | -0.34 | -0.35 | -0.06 | -0.22 |
2021-09-30 | -0.27 | -0.30 | -0.32 | -0.08 | -0.21 |
2021-06-30 | -0.42 | -0.49 | -0.27 | 0.05 | -0.21 |
2021-03-31 | -0.35 | -0.40 | -0.28 | -0.18 | -0.20 |
2020-12-31 | -0.53 | -0.67 | -0.25 | -0.01 | -0.17 |
2020-09-30 | -0.48 | -0.60 | -0.20 | -0.00 | -0.14 |
Gross Margins
- marjin kotor untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -89.38.
- marjin bersih untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -150.80.
- marjin operasi untuk Adverum Biotechnologies, Inc. pada 2025 Jun 30 adalah -158.18.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | -89.38 | -150.80 | -158.18 |
2025-03-31 | -129.62 | -94.11 | -102.88 |
2024-12-31 | -129.62 | -94.11 | -102.88 |
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | -20.58 | -32.55 | -34.38 |
2023-12-31 | -22.03 | -35.05 | -35.27 |
2023-09-30 | -25.27 | -37.06 | -37.07 |
2023-06-30 | -0.45 | -37.06 | -37.07 |
2023-03-31 | -40.47 | -39.56 | |
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | -10.89 | ||
2021-12-31 | -10.92 | -19.41 | -19.34 |
2021-09-30 | -9.93 | -19.84 | -19.60 |
2021-06-30 | -9.93 | -18.42 | -18.34 |
2021-03-31 | -9.47 | -16.40 | -16.37 |
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1501756 |
Grupong Pang-industriya
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech) |